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Abstract
Porcine xenotransplants may offer a potential solution to the problem posed by the limited supply of allotransplants. However,
xenotransplantation may be associated with the risk of transmission of microorganisms, in particular of porcine endogenous retroviruses
(PERVs) that are an integral part of the porcine genome and able to infect human cells in vitro. Possible strategies to prevent virus
transmission include the development of PERV knockout animals or of effective vaccines. When antisera prepared against the main
structural proteins of PERV were screened, a goat antiserum against the recombinant ectodomain of the transmembrane envelope protein
p15E was found to neutralize PERV infectivity. Epitope mapping using overlapping peptides revealed two epitopes, E1 (GPQQLEK) and
E2 (FEGWFN). These sequences are identical for all PERVs and are highly conserved among all gammaretroviruses. Interestingly,
antibodies isolated from AIDS patients and specific for sequences of HIV-1 partially homologous with E2 (Mab4E10, LWNWFN) or located
in close proximity to E2 (Mab2F5, ELDKWA) are known to neutralize several strains of HIV-1. It is the first report showing epitope
mapping of gammaretrovirus-specific neutralizing antibodies and demonstrating similarity to corresponding epitopes in HIV. These domains
of the transmembrane proteins of different retroviruses are an effective target for neutralizing antibodies and may be a useful antigen to
create an antiretroviral vaccine.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Xenotransplantation is a possible solution to overcoming
the shortage of allografts for transplantation. Pigs are cur-
rently the most favored donors of organs and tissues for
xenotransplantation. However, the use of organs across the
species barrier may be associated with the risk of transmis-
sion of microorganisms, especially porcine endogenous ret-
roviruses (PERVs), which are an integral part of the porcine
genome (Patience et al., 2001) and infect human cells in
vitro (Patience et al., 1997; Specke et al., 2001a). It is still
unknown whether PERVs can infect human transplant re-
cipients in vivo and, if so, whether they are pathogenic.
PERVs are closely related to retroviruses such as the feline
and murine leukemia viruses, which induce in the infected
host leukemias and immune deficiencies (Denner, 1987).
There are several possible approaches to preventing PERV
transmission to the transplant recipient. First, animals may be
produced which do not release human-tropic infectious virus,
either by conventional breeding (Oldmixon et al., 2002) or by
using genetic knockout technologies already developed in pigs
to reduce the hyperacute rejection against galactose-1,3-ga-
lactose epitopes (Dai et al., 2002; Lai et al., 2002).
Many of the more than 50 proviral copies located in the
pig genome are unable to produce infectious virus due to
deletions and mutations. Such defective viruses have been
found in many other species, including man (Lo¨wer et al.,
1996). However, infectious particles may be produced not
only by replication-competent viruses, but also as the result
of recombination and/or complementation of intact genes
from defective proviruses.
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Second, as transplantation is usually a medical interven-
tion planned a long time in advance, it would be feasible to
vaccinate transplant recipients against PERV. While the
development of a vaccine against lentiviruses such as HIV
has not been very successful to date (Liu, 1998; Schultz and
Stott, 1994), effective vaccines against type C retroviruses
(now termed gammaretroviruses), such as MuLV and
FeLV, exist (Lee et al., 1977; Montelaro and Bolognesi,
1995; Peters et al., 1975). Leukemia-preventing antibodies
were predominantly induced by immunization with recom-
binant envelope proteins gp 70 and p15E (Marciani et al.,
1991). However, none of the five commercial FeLV vac-
cines currently available in the USA and Europe provide
100% protection against infection. Three are composed of
inactivated whole virus and two are gp70 subunit vaccines
(Marciani et al., 1991; Sparkes, 1997). Since PERVs are
gammaretroviruses closely related to MuLV and FeLV, an
effective vaccine against PERV may be a real possibility.
Here we describe an antiserum specific for the trans-
membrane envelope protein p15E of PERV with strong
neutralizing activity. This antiserum was developed for
several reasons: (i) To develop an approach to immuni-
zation against and prevention of PERV transmission in
xenotransplantation. The transmembrane envelope (TM)
protein was used because we intended to create a vaccine
neutralizing the virus but not being harmful for the trans-
plant and only p15E has conformational intermediates
not present on the budding or free virus but generated
during infection (fusion-competent conformations). (ii)
To evaluate our immunological detection methods, such
as Western blot assays and ELISAs (Tacke et al., 2001),
and as additional tool to study the immunosuppressive
properties of p15E (Denner, 1997, 1998; Tacke et al.,
2000). (iii) To study this immunization approach and to
apply it—if possible—to other retroviruses, including
HIV, since broadly neutralizing antibodies directed
against the TM protein of HIV-1 were described (Muster
et al., 1993). Interestingly, the epitopes recognized by
the PERV-specific serum are located in a domain of
p15E that is highly conserved among gammaretroviruses
and which shares homology with regions of the HIV-1
gp41 known to induce neutralizing activity against dif-
ferent clades of HIV-1 (Zwick et al., 2001). This domain
may therefore serve as a basis for the development of
preventive vaccines to block PERV infection in xeno-
transplant recipients. The data presented here may have
implications for antiretroviral vaccine development in
general.
Results
Reactivity of the p15E-specific antiserum
In order to generate a p15E-specific antiserum, the re-
combinant ectodomain of p15E (amino acids 488–597) was
produced using a cloned PERV-A sequence derived from
PERV-producing PK-15 pig kidney cells by PCR amplifi-
cation. The protein was successfully expressed as a calmod-
ulin binding peptide(CBP) fusion protein in Escherichia
coli and purified by CBP affinity chromatography. The
protein had a molecular mass of 12 kDa compared to the 18
kDa of viral p15E (Fig. 1A). Immunization of a goat yielded
antiserum recognizing p15E in purified virus preparations,
purified viral p15E, and the recombinant protein used for
immunization as shown by Western blot analysis (Fig. 1A).
It also reacted with the recombinant p15E in an ELISA, but
it did not contain antibodies directed against the immuno-
suppressive domain of p15E thought to be involved in
retrovirus-induced immunosuppression (Denner, 1998). The
preimmune serum did not react in any assay (Fig. 1B).
Fig. 1. Reactivity of a goat antiserum specific for PERV p15E. (A) Western blot analysis using highly purified PERV (1), highly purified viral p15E (2), or
the recombinant ectodomain of p15E as used for immunization (3). The molecular mass of the proteins is indicated on the left. (B) Determination of ELISA
titers using the recombinant ectodomain of p15E: gray columns, immune serum; white columns, preimmune serum.
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Neutralizing activity of the p15E-specific antiserum
Heat-inactivated (56°C, 30 min) serum was shown to
inhibit infection of human 293 kidney cells by PERV/5°, a
recombinant virus with the PERV-A receptor binding site
(Fig. 2). This virus, generated by serial passage of PERV-
NIH/3° (Wilson et al., 1998, 2000) on human 293 kidney
cells, is characterized by high infectivity and genetic alter-
ations in the LTR (Denner et al., 2001, 2002). The preim-
mune serum had no neutralizing activity. When antibodies
purified by affinity chromatography using immobilized
p15E were used in the neutralization assay, a clear inhibi-
tion was seen (Fig. 2). This indicates that the neutralizing
activity is based on antibodies, not on complement or other
soluble antiviral factors.
Epitope mapping
To analyze the epitopes against which the neutralizing
antibodies were directed, linear 13-mer peptides overlap-
ping by 11 amino acids and corresponding to the entire
sequence of p15E of PERV-A were used. These peptides
were bound covalently by the C-terminus to a cellulose
membrane. Two main epitopes were found (Fig. 3A), one
located at the N terminus (E1, GPQQLEK) and the other at
the C terminus (E2, FEGWFN). As expected, these epitopes
were part of the sequence used for immunization (Fig. 3B).
The sequences corresponding to the epitopes are conserved
among all PERVs (PERV-A, PERV-B, PERV-C) and are
homologous to sequences in the transmembrane envelope
protein of other gammaretroviruses and partially related to
corresponding sequences in the transmembrane envelope
protein of lentiviruses such as HIV-1 (Fig. 3C).
Antibodies purified by affinity chromatography using
immobilized p15E reacted in an ELISA with the peptides
E1, E2, E1 and E2, as well as with purified recombinant
p15E (Fig. 4). They did not react with the immunosuppres-
sive (isu) peptide, indicating the specificity of the reaction.
It remains unclear whether the additive effect when both
peptides were added simultaneously is due to a reaction
with a discontinuous epitope.
Inhibition of the neutralizing activity with peptides
corresponding to the epitopes E1 and E2
To determine whether antibodies binding to the epitopes
mapped were indeed responsible for the neutralizing activ-
ity, inhibition studies were performed. Affinity-purified
neutralizing antibodies were preincubated with recombinant
p15E and with both synthetic peptides. An inhibition of
neutralization was observed when p15E, E1, and E2 were
added (Fig. 5). No inhibition was seen when the control isu
peptide was added. These data indicate that antibodies spe-
cific for both epitopes are responsible for the neutralizing
activity.
Discussion
Xenotransplantation represents one approach to over-
coming the shortage of organs required to treat patients with
severe organ failure. In Germany, for example, 550 heart
and 2300 kidney transplantations are performed annually.
However, over 2000 heart and 11,000 kidney patients re-
main on the waiting list, of whom 25% die before receiving
the lifesaving organ. Alternative approaches include the
prevention of those diseases leading to the loss of organ
function or the generation of new organs from stem cells.
Since stem cell research is in its infancy, xenotransplanta-
tion seems at present to be the only reasonable approach.
However, before xenotransplantation becomes a clinical
reality, three main criteria have to be met: prevention of
immunological rejection, physiological compatibility, and
microbiological safety. Whereas most microorganisms of
the pig that may infect humans and lead to xenozoonoses
may be eliminated by breeding of specified pathogen-free
(SPF) animals, PERVs cannot be eliminated so easily.
Fig. 2. Neutralization of PERV/5° by the goat antiserum specific for p15E. Infection was measured by PCR detecting provirus integration. Virus-containing
supernatant was diluted 1:2 in the absence of serum (A), in the presence of preimmune serum diluted 1:5 (B), in presence of the immune serum diluted 1:5
(C), and in the presence of affinity-purified antibodies (100 g/ml) (D). The size of the amplicon (817 bp) is indicated on the left.
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Although the knockout technology is established for pigs
(Lai et al., 2002; Dai et al., 2002), it remains unclear
whether the elimination of replication-competent human-
tropic viruses would be sufficient or whether the remaining
non-replication-competent viruses may complement each
other. In addition, recombinations between human-tropic
and ecotropic PERVs have often been observed when pig
lymphocyte-derived PERVs infect human cells (Wilson et
al., 1998, 2000). Therefore the generation of a vaccine may
be an appropriate solution to preventing PERV transmission
to human recipients. Such a vaccine should be directed
against all PERVs produced by pig cells and should not
harm the transplant if the virus is expressed or budding on
the cell surface.
The generation of an antiretroviral vaccine is also of
broad academic and public interest. The urgent need for the
production of vaccines against retroviruses was initiated by
the discovery that members of this family cause leukemia
and acquired immune deficiency syndrome (AIDS) in hu-
mans. It is well known that the HIV epidemic represents a
transpecies transmission of SIV in vivo (Gao et al., 1999),
and PERVs may also therefore be a risk for patients and
contact persons during xenotransplantation. The potential
for transspecies transmission may be enhanced by the ab-
sence of normal antiviral immune responses resulting from
the pharmacological immunosuppression needed to prevent
transplant rejection. Although in vivo transspecies transmis-
sion of PERV was recently claimed in SCID mice (Deng et
al., 2000; van der Laan et al., 2000) other attempts to infect
immunosuppressed small animals and nonhuman primates
failed (Denner et al., 2001; Specke et al., 2002, 2001b). In
addition, no evidence for PERV infection was found in
experimental pig-to-human xenotransplantations, including
ex vivo perfusion (Paradis et al., 1999; Tacke et al., 2001).
The limited contact with porcine tissues, the small number
Fig. 3. Epitope mapping of neutralizing antibodies specific for PERV p15E. The result of the dot blot ECL method using overlapping peptides is given in
A. In B the sequence of p15E of PERV-A is given, the sequence of the recombinant protein used for immunization is printed in bold, and the epitopes are
framed. In addition, a comparison of the sequence of the epitopes with corresponding sequences of other retroviruses is given in C.
Fig. 4. ELISA reactivity of the PERV p15E-specific antiserum specific
using recombinant p15E and synthetic peptides corresponding to the
mapped E1 and E2 epitopes. As a control a peptide corresponding to the
immunosuppressive (isu) domain was used.
409U. Fiebig et al. / Virology 307 (2003) 406–413
of pig cells, and the absence of strong pharmacological
immunosuppression might have contributed to the lack of
PERV transmission. Therefore the possibility that extended
contact with the implanted porcine cells or inoculation of
larger amounts of PERV could result in an infection cannot
be excluded.
Vaccines against gammaretroviruses related to PERV,
such as FeLV and MuLV, exist, but their efficacy should be
improved (Sparkes, 1997). Several regions that elicit FeLV-
neutralizing antibodies were defined on the outer membrane
protein gp70 and on the transmembrane protein p15E (Elder
et al., 1987). It was shown that immunization with gp70 and
p15E is more effective than immunization with gp70 alone
(Schwarz et al., 1984). Interestingly, one of the peptides
inducing neutralizing antibodies, 17B (Elder et al., 1987),
derived from the C-terminal transmembrane region of p15E
of FeLV, contains the epitope E2 (FEGWFN) described
here. This epitope is highly conserved among gammaretro-
viruses. Peptid C18B, derived from the N-terminal region
near the fusion peptide, also induces neutralizing antibodies
and contains a sequence corresponding to epitope E1. Both
peptides had been conjugated to keyhole limpet hemocyanin
for immunization of rabbits; however, no epitope mapping
of the neutralizing sera was performed.
At present, the main goal of many researchers is the
generation of an AIDS vaccine. Numerous attempts to gen-
erate such a vaccine have failed (Montelaro and Bolognesi,
1995). However, broadly neutralizing monoclonal antibod-
ies against the TM protein gp41 of HIV-1 have been pre-
pared from HIV-1-seropositive individuals (Muster et al.,
1993; Zwick et al., 2001). Both monoclonal antibodies
(Mab 2F5/Mab 4E10) recognize a relatively conserved re-
gion in gp41 close to the viral membrane (Fig. 6). However,
immunization with synthetic peptides corresponding to the
sequence of 2F5 or 4E10 did not result in neutralizing
antibodies (Liao et al., 2000; Lu et al., 2000; Tian et al.,
2001; Xiao et al., 2000), suggesting some conformational
requirements of the vaccine (Zwick et al., 2001).
The conformation of epitopes in the transmembrane en-
velope protein of different retroviruses recognized by neu-
tralizing antibodies is unclear, although results suggest that
possibly the neutralizing antibodies bind to a discontinuous
epitope. Being conserved, the C-terminal extracellular re-
gion is an obvious candidate for inducing broadly reactive
neutralizing antibodies. There are two mechanisms by
which the neutralizing activity may be explained. First, after
binding of the viral surface envelope protein gp70 to its
corresponding (yet unknown) receptor and conformational
changes in the transmembrane envelope protein p15E the
interaction of the C-terminal helix with the N-terminal helix
of p15E brings the epitopes E1 and E2 in close proximity
and the neutralizing antibodies may bind to the epitopes E1
and E2 and prevent fusion of the viral membrane with the
cellular membrane. Second, despite the fact that most of the
transmembrane envelope protein is occluded by the surface
envelope protein gp70, the domains corresponding to E1
and E2 may be free, allowing binding of the neutralizing
antibodies that then prevent, due to their size, the binding of
the surface envelope protein to the receptor. The latter
Fig. 5. Inhibition of the neutralizing activity of the antiserum specific for PERV p15E. Virus was diluted 1:2 in the absence of serum (A) or in the presence
of 100 g/ml of affinity chromatography-purified neutralizing antibodies (B–F). (B) Shown are dilution of the virus without inhibitor (with medium alone),
(C) the inhibition of the neutralizing activity by 25 g/well of recombinant p15E, (D) by the synthetic peptide corresponding to the epitopes E1 (25 g/well),
(E) to the epitope E2 (25 g/well), and (F) by a mixture of E1 and E2 (12.5 g/well  12.5 g/well).
Fig. 6. Localization of the epitopes E1 and E2 in p15E of PERV (A) and
localization of epitopes in gp41 of HIV-1 recognized by neutralizing
antibodies in HIV-infected individuals (B).
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mechanism was also proposed by Zwick et al. (2001) for
neutralization of HIV by Mab 2F5 and Mab 4E10.
Experiments are under way to reproduce the induction of
such neutralizing antibodies against PERV as a first step
toward the generation of a vaccine that may prevent virus
infection but does not harm the xenotransplant as well as to




PERV/5° and human kidney 293 cells were used for
titration studies. PERV/5° was derived from PERV-NIH/3°
(kindly provided by C. Wilson, FDA, Bethesda, MD) (Wil-
son et al., 1998, 2000) by serial passages on human 293
cells. PERV/5° is characterized by genetic changes in the
LTR and a higher infectious yield in comparison to PERV-
NIH/3° (Denner et al., 2001, 2002).
Generation of recombinant p15E
DNA from PERV-producing PK-15 pig kidney cells was
isolated using a Qiagen DNA isolation kit. Using the for-
ward primer 5GTA CGT ACG TGG ATC CCT AAT CAC
AGG ACC GCA ACA and the reverse primer 5ACG TAC
GTA CGA ATT CTC AGT TGA ACC ATC CTT AAA
ACC A a sequence corresponding to the ectodomain of the
transmembrane envelope protein p15E (amino acids 488–
597) was amplified by polymerase chain reaction and
cloned into the pCal-n vector (Stratagene, Europe, Amster-
dam, Netherlands). E. coli BL21 DE3 cells were trans-
formed and rp15E N-terminally fused to a 4 kDa CBP was
produced. The fusion protein was purified by calmodulin
resin affinity chromatography (Stratagene). For immuniza-
tion and for inhibition experiments the protein was exten-
sively dialyzed against phosphate-buffered saline (PBS).
Immunization
To generate rp15E-specific antibodies, a goat was inoc-
ulated im twice (0 and 4 weeks) with 0.5 mg of the affinity-
purified recombinant fusion protein emulsified in Freund’s
adjuvant.
Affinity chromatography of neutralizing antibodies
Purified rp15E was coupled to CNBr-activated Sepha-
rose (Pharmacia) and specific antibodies were eluted using
Tris–glycine buffer, pH 2.3. The antibodies were dialyzed
against PBS.
Purification of viral p15E
To purify viral p15E, PERV/5° particles were pelleted
and purified by sucrose centrifugation. The particles were
freeze-thawed twice and than dissolved in TEN buffer (50
mM Tris, 1 mM EDTA, 100 mM NaCl, pH 7.4) with 0.1%
Triton X-100. The lysate was centrifuged at 100,000 g for
2 h at 4°C to remove insoluble material. The second step of
the purification procedure consisted of immunoaffinity
chromatography. Purified antibodies from the goat anti-
p15E serum were coupled to NHS-activated Sepharose 4
Fast Flow (Pharmacia Biotech, Uppsala, Sweden). The viral
lysate was applied to the immunoaffinity column preequili-
brated in TEN with 0.1% Triton X-100. After washing with
the same buffer, p15E was eluted with 0.5 M propionic
acid/0.1% Triton X-100 (pH 2.5) and the eluant was col-
lected into tubes containing 2 M Tris–0.1% Triton X-100
(pH 7.6). The purity was verified by SDS–PAGE and silver
staining.
Peptides and ELISA
The following peptides were used: the immunosuppres-
sive peptide of PERV-A (isu-peptide), synthesized as de-
scribed (Denner et al., 1994; Tacke et al., 2000) and E1 and
E2 (both synthesized by Jerini Biotools, Berlin, Germany).
Peptide ELISA was performed as described (Denner et al.,
1994); 1 g per well of peptide or recombinant p15E was
coated onto Nunc-Immunoplates (Nalge Nunc, Denmark)
Electrophoresis and immunoblotting
SDS–PAGE and Western blotting were performed as
described (Tacke et al., 2001); 10 g of purified PERV/5°
and 1 g of purified viral or recombinant p15E was used as
antigen per lane.
In vitro neutralization assays
Neutralization assays were performed on human kidney
293 cells. A cell suspension (100 l) containing 4500 cells
per well was seeded into 96-well microtiter plates and 2
days later, cells were infected with cell-free virus-contain-
ing supernatant of PERV/5°-infected 293 cells (1  104.31
TCID50/ml). Cells were split 1:3 after 3 days. After 6 days
infected cells were detected by PCR using the forward
primer 5GTA CGT ACG TGG ATC CCT AAT CAC AGG
ACC GCA ACA and the reverse primer 5ACG TAC GTA
CGA ATT CTC AGT TGA ACC ATC CTT AAA ACC
from the pol region of PERV. For this cells were freeze-
thawed three times and lysis buffer containing 20 mg/ml of
proteinase K in PCR buffer (50 mM KCl, 1.5 mM MgCl2,
10 mM Tris–HCL, pH 8.4) was added for 3 h at 56°C. To
inhibit proteinase K activity, the solution was subsequently
incubated for 10 min at 95°C. In the inhibition experiments
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recombinant p15E and peptides were dissolved in PBS and
added at a concentration of 25 g/well.
Mapping of epitopes
The entire amino acid sequence of p15E/PERV A was
synthesized as a cellulose-adsorbed peptide spot library of
13-mer peptides, overlapping by 11 amino acids (Jerini
Biotools) using a standard protocol (Kramer and Schneider-
Mergener, 1998). The membrane was incubated with a
1:5000 immune serum solution (for control with preimmune
serum) for 3 h, washed three times with Tris-bufferd saline,
pH 7.5, with 0.05% Tween 20 (Sigma) for 15 min, and
incubated for 2 h with peroxidase-conjugated secondary
antibody diluted 1:10,000. Binding was detected using a
chemiluminescence detection solution (ECL, Amersham
Pharmacia Biotech).
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